scholarly journals CLINICAL EVALUATION OF THE EFFECT OF SHTAVARIYADI KSHEERAPAKA ON PERIMENOPAUSAL SYNDROME

2021 ◽  
Vol 12 (3) ◽  
pp. 31-33
Author(s):  
Aswathi Sara Varghese ◽  
Sandhya K
Keyword(s):  
Side Effects ◽  
Life Span ◽  
Effective Treatment ◽  
Treatment Option ◽  
Clinical Evaluation ◽  
Modern Medicine ◽  
Physiological Changes ◽  
Effective Treatment Option ◽  
Hormonal Level ◽  
Perimenopausal Syndrome

Menopause is an important phase in women’s life. However, alteration in hormonal level leads to many undefined anatomical and physiological changes in women. As women spend near one third of their life span after menopause, the consequences of menopause are also experience for a longer period of time. In Ayurveda classics, Artava Nivritti or menopause is considered as a normal physiology of Jaravastha, and hence, its effects on body are not explained directly. The treatments available for menopause in the modern medicine come with many known side effects. According to, the period of menopause belongs to Parihanikala, leading to Vriddhavastha. Therefore, Rasayana can be considered as an effective treatment option. On this basis, a Ksheerapaka named as Shatavariyadi Ksheerapaka has been formulated. It comprises of a mixture of powders of Ashwagandha, Shatavari, Guduchi and Yashtimadhu. Shatavariyadi Ksheerapaka shows significant reduction in the symptoms of perimenopausal syndrome.

Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours

2019 ◽  
Vol 12 (2) ◽  
pp. 126-134 ◽  
Author(s):  
Shahad Alsadik ◽  
Siraj Yusuf ◽  
Adil AL-Nahhas
Keyword(s):  
Side Effects ◽  
Effective Treatment ◽  
Radionuclide Therapy ◽  
Neuroendocrine Tumours ◽  
Peptide Receptor Radionuclide Therapy ◽  
Progression Free Survival ◽  
Treatment Modalities ◽  
Effective Treatment Option ◽  
Peptide Receptor ◽  
Pancreatic Neuroendocrine Tumours

Background: The incidence of pancreatic Neuroendocrine Tumours (pNETs) has increased considerably in the last few decades. The characteristic features of this tumour and the development of new investigative and therapeutic methods had a great impact on its management. Objective: The aim of this review is to investigate the outcome of Peptide Receptor Radionuclide Therapy (PRRT) in the treatment of pancreatic neuroendocrine tumours. Methods: A comprehensive literature search strategy was used based on two databases (SCOPUS, and PubMed). We considered all studies published in English, evaluating the use of PRRT (177Luteciuim- DOTA-conjugated peptides and 90Yetrium- DOTA- conjugated peptides) in the treatment of pancreatic neuroendocrine tumours as a standalone entity or as a subgroup within the wider category of Gastroenteropancreatic Neuroendocrine Tumours (GEP NETs). Results: PRRT was found to be an effective treatment modality as a monotherapy or in combination with other therapies in the treatment of non-operable and metastatic pNETs where other options are limited. Complete response was reported to be between 2-6% while partial response was achieved in up to 60% of cases. Survival analysis was also impressive. Progression Free Survival (PFS) reached a mean of 34 months and Overall Survival (OS) of 53 months. PRRT also proved to improve patients’ Quality of Life (QoL). Acute and sub-acute side effects like nephrotoxicity and haematotoxicity are usually mild and reversible. Conclusion: PRRT is well tolerated and effective treatment option for non-operable and/or metastatic pNETs. Side effects are usually mild and reversible. Larger randomized controlled trails need to be done to compare PRRT with other treatment modalities and to provide more detailed guidelines regarding patient selections, the choice of PRRT, follow up and response assessment to maximum potential benefit.

scholarly journals COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease

2020 ◽  
Vol 4 (18) ◽  
pp. 4278-4281 ◽  
Author(s):  
Zahidee Rodriguez ◽  
Andi L. Shane ◽  
Hans Verkerke ◽  
Christopher Lough ◽  
Matthew G. Zimmerman ◽  
...  
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Effective Treatment ◽  
Treatment Option ◽  
Congenital Heart ◽  
Effective Treatment Option ◽  
Immune Systems ◽  
Key Points ◽  
Donor Variability

Key Points COVID-19 convalescent plasma (CP) may be a safe and effective treatment option in SARS-CoV-2 infection refractory to remdesivir. Infants may benefit from CP despite developing immune systems and donor variability emphasizes the need for characterization prior to use.

scholarly journals Gentamicin susceptibility among a sample of multi-drug resistantNeisseria gonorrhoeaeisolates in India

2016 ◽  
pp. AAC.01907-16 ◽  
Author(s):  
Manju Bala ◽  
Vikram Singh ◽  
Aradhana Bhargava ◽  
Monika Kakran ◽  
Naveen Chandra Joshi ◽  
...  
Keyword(s):  
Effective Treatment ◽  
Treatment Outcomes ◽  
Treatment Option ◽  
Antimicrobial Susceptibility ◽  
Susceptibility Testing ◽  
Dual Therapy ◽  
Clinical Treatment ◽  
Antimicrobial Susceptibility Testing ◽  
Effective Treatment Option

Antimicrobial susceptibility testing of 258N. gonorrhoeaeisolates by Etest determined that 60.1% were MDR while 5% strains had decreased susceptibility to currently recommended extended-spectrum cephalosporins (ESCs). Among these, 84.5% MDR and 76.9% strains having decreased susceptibility to ESCs were susceptible to gentamicin. No MDR isolate was resistant to gentamicin. Thesein vitroresults suggest that gentamicin might be an effective treatment option for the MDR strains and in dual therapy for gonorrhea. However, further research regarding the clinical treatment outcomes is essential.

scholarly journals P2.05-030 WBRT Prior EGFR TKIs is Effective Treatment Option for NSCLC Patients with CNS Metastases Harboring EGFR Mutation

2017 ◽  
Vol 12 (1) ◽  
pp. S1048-S1049
Author(s):  
Pawel Krawczyk ◽  
Marcin Nicoś ◽  
Dariusz Kowalski ◽  
Rodryg Ramlau ◽  
Kinga Winiarczyk ◽  
...  
Keyword(s):  
Effective Treatment ◽  
Treatment Option ◽  
Egfr Mutation ◽  
Cns Metastases ◽  
Effective Treatment Option ◽  
Nsclc Patients ◽  
Egfr Tkis

Thyroidectomy remains an effective treatment option for Grave’s disease

2007 ◽  
Vol 194 (2) ◽  
pp. 270 ◽  
Author(s):  
Anand Kumar Mishra ◽  
C.K. Ben Selven ◽  
Aravindan Nair ◽  
Amit Agarwal
Keyword(s):  
Effective Treatment ◽  
Treatment Option ◽  
Effective Treatment Option ◽  
Grave’S Disease ◽  
Grave's Disease

scholarly journals Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide

2018 ◽  
Vol 103 (5) ◽  
pp. 540-545 ◽  
Author(s):  
Jean-Yves Reginster ◽  
Gary Hattersley ◽  
Gregory C. Williams ◽  
Ming-yi Hu ◽  
Lorraine A. Fitzpatrick ◽  
...  
Keyword(s):  
Effective Treatment ◽  
Postmenopausal Osteoporosis ◽  
Treatment Option ◽  
Number Needed To Treat ◽  
Effective Treatment Option
Sign in / Sign up

Export Citation Format

Share Document